[Federal Register Volume 61, Number 190 (Monday, September 30, 1996)]
[Notices]
[Pages 51121-51122]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-25021]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Therapeutic Polyamines

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice is in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.8(a)(1)(I) that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive world-wide license to practice the inventions embodied in 
U.S. Patent No. 5,541,230 and a divisional thereto (U.S. Patent 
Application No. to be assigned) to S'LIL Pharmaceuticals of Madison, 
Wisconsin.

    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    Most previous attempts to retard the growth of tumor cells by 
depleting the intracellular polyamine pool have been directed at 
inhibiting enzymes in the polyamine biosynthetic pathway; a process 
that does not completely deplete endogenous stores of these molecules. 
To date, most attempts at using polyamine biosynthetic inhibitors

[[Page 51122]]

have resulted in incomplete inhibition of cell growth. U.S. Patent No. 
5,541,230 is directed towards synthetic polyamines which bind DNA, but 
do not function as natural polyamines and, indeed, cause almost 
complete depletion of intracellular stores of these compounds. These 
compounds have shown great promise in vitro and in vivo against tumors. 
Additionally, these synthetic polyamines sensitize tumors in 
conjunction with other conventional chemotherapeutics in vivo.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Allan M. Kiang, Technology Licensing Specialist, 
Office of Technology Transfer, National Institutes of Health, 6011 
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; 
Telephone: (301) 496-7735 ext. 270; Facsimile: (301) 402-0220. A signed 
Confidentiality Agreement will be required to receive copies of the 
patent applications. Applications for a license in the field of use 
filed in response to this notice will be treated as objections to the 
grant of the contemplated licenses. Only written comments and/or 
applications for a license which are received by NIH on or before 
November 29, 1996 will be considered. Comments and objections submitted 
to this notice will not be made available for public inspections and, 
to the extent permitted by law, will not be released under the Freedom 
of Information Act, 5 U.S.C. 552.

    Dated: September 18, 1996.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 96-25021 Filed 9-27-96; 8:45 am]
BILLING CODE 4140-01-M